The latest report by IMARC Group, titled" Viral Vector Manufacturing Market Report by Type (Adenoviral Vectors, Adeno-associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others), Disease (Cancer, Genetic Disorders, Infectious Diseases, and Others), Application (Gene Therapy, Vaccinology), End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes), and Region 2024-2032", offers a comprehensive analysis of the industry, which comprises insights on the market. The global viral vector manufacturing market size reached US$ 1,200.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 7,681.6 Million by 2032, exhibiting a growth rate (CAGR) of 22.4% during 2024-2032.
Factors Affecting the Growth of the Viral Vector Manufacturing Industry:
Increasing Prevalence of Genetic Disorder:
The rising incidence of genetic disorders and chronic diseases such as cancer and neurological disorders has significantly driven the demand for effective therapies, placing gene therapy at the forefront of medical research. Viral vectors, crucial in delivering genetic material into cells to rectify genetic errors, have become indispensable. With an increasing number of genetic ailments lacking definitive treatments, the urgency for novel and efficient therapeutic methods has escalated. This trend is compelling pharmaceutical companies to invest heavily in the development of gene therapies, thereby boosting the viral vector manufacturing market. Moreover, the success of these therapies in clinical trials and their potential to offer long-lasting and potentially curative outcomes encourages further research and development, expanding the scope of viral vector applications.
Regulatory Support:
Governments and regulatory bodies worldwide are increasingly recognizing the potential of gene therapies in treating previously untreatable conditions. This recognition is translating into more robust regulatory frameworks and faster approvals for gene therapy products. Simultaneously, there is significant public and private funding being directed towards research in gene therapy, including the development and scaling of viral vector manufacturing capabilities. Financial incentives, grants, and subsidies are being provided to support the burgeoning field of gene therapy. For example, initiatives like the U.S. FDA’s Fast Track and Breakthrough Therapy designations expedite the review process for gene therapies addressing severe conditions. This supportive regulatory environment accelerates the development and approval of gene therapies and enhances investor confidence, driving further investments into viral vector manufacturing.
Technological Advancements:
Technological advancements in biotechnology and gene editing, particularly the refinement of CRISPR-Cas9 and other gene-editing tools, have revolutionized the field of medicine by enabling precise genetic alterations at the cellular level. These innovations enhance the effectiveness and safety of gene therapies that rely on viral vectors for delivery. The integration of cutting-edge technology facilitates the development of more robust and scalable viral vector manufacturing processes, crucial for meeting the growing demand from clinical research and therapeutic applications. Additionally, these advancements are reducing the cost and complexity of production, making gene therapy more accessible and feasible for a broader range of conditions. The continuous evolution in biotechnological techniques is likely to propel the expansion of the viral vector manufacturing market as more tailored and potent gene therapies reach the market.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/viral-vector-manufacturing-market/requestsample
Leading Companies Operating in the Global Viral Vector Manufacturing Market
Cognate BioServices Inc. (Charles River Laboratories International Inc.)
F. Hoffmann-La Roche AG
FinVector Oy
FUJIFILM Holdings Corporation
Kaneka Eurogentec S.A. (Kaneka Corporation)
Lonza Group AG
Merck KGaA
Oxford Biomedica plc
REGENXBIO Inc.
Sanofi S.A.
Thermo Fisher Scientific Inc.
uniQure N.V.
Viral Vector Manufacturing Market Report Segmentation:
By Type:
Adenoviral Vectors
Adeno-associated Viral Vectors
Lentiviral Vectors
Retroviral Vectors
Others
Adeno-associated viral vectors hold the largest market share as they are considered relatively safe compared to other viral vectors.
By Disease:
Cancer
Genetic Disorders
Infectious Diseases
Others
Cancer dominates the market due to the high demand for innovative treatments in oncology.
By Application:
Gene Therapy
Vaccinology
Gene therapy holds the largest market share as it is used to treat a wide range of genetic disorders, including inherited diseases, cancer, and rare diseases.
By End User:
Pharmaceutical and Biopharmaceutical Companies
Research Institutes
Based on the end user, the market has been divided into pharmaceutical and biopharmaceutical companies and research institutes.
Regional Insights:
North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa
North America’s dominance in the viral vector manufacturing market is attributed to well-established biopharmaceutical industry with a strong focus on research and development of novel therapeutics, including gene and cell therapies.
Global Viral Vector Manufacturing Market Trends:
Gene therapy has emerged as a promising approach for treating a wide range of genetic and acquired diseases, driving the demand for viral vectors as delivery vehicles for therapeutic genes. The increasing number of clinical trials and approvals of gene therapy products has fueled the growth of the viral vector manufacturing market. Besides, ongoing research efforts are focused on improving the safety, efficacy, and specificity of viral vectors for gene delivery. Advancements in viral vector design, such as the development of novel capsids, promoters, and targeting ligands, are enhancing the performance of viral vectors and expanding their applicability in gene therapy.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Write a comment ...